Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.
At the 2022 Tandem Meeting, CancerNetwork® spoke with Nina Shah, MD, a hematologist oncologist from University of California, San Francisco Health, about the reasoning behind conducting the phase 2 KarMMA trial (NCT03361748) which analyzed idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory multiple myeloma who have received 4 or more lines of therapy. In particular, the study focuses on correlates of complete response (CR) to ide-cel.
We recently performed a sub-analysis of the KarMMA study looking at patients who achieved a CR or not. Now to recap, the patients who [achieved] a CR did very well as far as PFS [progression-free survival] goes. We wanted to better understand what it was about those patients that allowed them [to achieve] or was correlated with achieving a CR which correlated with higher PFS. We performed an analysis of baseline correlatives of CR, to bb2121 or ide-cel, to understand how we might be able to select patients better.
Shah N, Munshi N, Berdeja JG, et al. Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma (RRMM): subanalysis of the KarMMa trial. Presented at the 2022 Tandem Meetings; April 22-26, 2022; Salt Lake City, UT. Poster 223.